EMvision Medical Devices Limited, a medical device company, engages in the research, development, and commercialization of imaging and diagnostic technology products.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$2.94|
|52 Week High||AU$2.10|
|52 Week Low||AU$4.20|
|1 Month Change||-1.34%|
|3 Month Change||12.64%|
|1 Year Change||3.52%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||863.93%|
Recent News & Updates
We're Not Very Worried About EMvision Medical Devices' (ASX:EMV) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
We're Not Very Worried About EMvision Medical Devices' (ASX:EMV) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. Indeed, EMvision Medical...
Here's Why We're Not Too Worried About EMvision Medical Devices' (ASX:EMV) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, EMvision...
|EMV||AU Medical Equipment||AU Market|
Return vs Industry: EMV exceeded the Australian Medical Equipment industry which returned -7.4% over the past year.
Return vs Market: EMV underperformed the Australian Market which returned 24.4% over the past year.
Stable Share Price: EMV is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: EMV's weekly volatility (6%) has been stable over the past year.
About the Company
EMvision Medical Devices Limited, a medical device company, engages in the research, development, and commercialization of imaging and diagnostic technology products. It develops a portable brain scanner for point of care, stroke diagnosis, and monitoring. The company was incorporated in 2017 and is based in Macquarie Park, Australia.
EMvision Medical Devices Fundamentals Summary
|EMV fundamental statistics|
Is EMV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EMV income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.11|
|Net Profit Margin||-494.36%|
How did EMV perform over the long term?See historical performance and comparison
Is EMvision Medical Devices undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EMV's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EMV's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EMV is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: EMV is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EMV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EMV is overvalued based on its PB Ratio (21.4x) compared to the AU Medical Equipment industry average (4.5x).
How is EMvision Medical Devices forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as EMvision Medical Devices has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has EMvision Medical Devices performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EMV is currently unprofitable.
Growing Profit Margin: EMV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EMV is unprofitable, and losses have increased over the past 5 years at a rate of 56.6% per year.
Accelerating Growth: Unable to compare EMV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EMV is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: EMV has a negative Return on Equity (-83.54%), as it is currently unprofitable.
How is EMvision Medical Devices's financial position?
Financial Position Analysis
Short Term Liabilities: EMV's short term assets (A$10.0M) exceed its short term liabilities (A$676.2K).
Long Term Liabilities: EMV's short term assets (A$10.0M) exceed its long term liabilities (A$43.8K).
Debt to Equity History and Analysis
Debt Level: EMV is debt free.
Reducing Debt: EMV had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EMV has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: EMV has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 46.5% each year.
What is EMvision Medical Devices's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EMV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EMV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EMV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EMV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EMV's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Ronald Peter Weinberger, also known as Ron, BSc (Hons), Ph D., AIMM, serves as Chief Executive Officer of EMvision Medical Devices Limited and serves as its Managing Director since May 6, 2020. Dr. Wei...
CEO Compensation Analysis
Compensation vs Market: Ron's total compensation ($USD1.95M) is above average for companies of similar size in the Australian market ($USD554.70K).
Compensation vs Earnings: Ron's compensation has increased whilst the company is unprofitable.
Experienced Management: EMV's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: EMV's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.
EMvision Medical Devices Limited's employee growth, exchange listings and data sources
- Name: EMvision Medical Devices Limited
- Ticker: EMV
- Exchange: ASX
- Founded: 2017
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$211.981m
- Shares outstanding: 73.10m
- Website: https://www.emvision.com.au
- EMvision Medical Devices Limited
- 65 Epping Road
- Suite 4.01
- Macquarie Park
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 07:01|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.